Search
Funded by a 5-year NHMRC Investigator grant to implement a strategy to eliminate rheumatic heart disease (RHD) as a public health problem in Australia.
In recent years, the interest in molecular diagnostic methods for the detection of many pathogens has grown substantially.
Benzathine penicillin G (BPG) has been in use since the 1950s for treatment of skin infections, bacterial pharyngitis, syphilis and prevention of recurrent episodes of acute rheumatic fever (ARF)
Reach works to promote the health of vulnerable populations by providing technical support to local, regional and global efforts to prevent and control rheumatic fever and rheumatic heart disease (RF/RHD).
This project aims to empower local clinicians with skills and knowledge of using handheld echocardiography (HAND) that will allow for mobile service provision into remote Indigenous communities.
The aim of this project is to conduct a situational analysis of the skin health services and activities currently available for managing skin infections within the Kimberley.
The Australian Strep A Vaccine Initiative (ASAVI) is an Australian-led global initiative with the goal of reducing the disease burden caused by Group A Streptococcus (Strep A) infection through effective vaccination.
The END RHD CRE will undertake a number of projects across several disciplines of research including epidemiology, biomedical sciences; implementation and translation; and understanding the RHD community with a special focus on documenting the experiences of those living with the disease.
This work will be undertaken in collaboration with The Kids Research Institute Australia and Australian based research teams to better understand how Penicillin works in Māori and Pacific children/teens who receive monthly BPG injections.
Asha Jonathan Bowen Carapetis AM BA MBBS DCH FRACP PhD GAICD FAHMS OAM AM MBBS FRACP FAFPHM PhD FAHMS Head, Healthy Skin and ARF Prevention Executive